Merck begins tender offer to acquire Idenix
23 June 2014 | By Merck
Merck is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc...
List view / Grid view
News
AbbVie declares quarterly dividend
23 June 2014 | By AbbVie
The board of directors of AbbVie Inc. declared a quarterly cash dividend of $0.42 per share...
Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo
23 June 2014 | By Novo Nordisk
New data from the phase 3a SCALE™ Diabetes trial were presented at the International Congress of Endocrinology and the Endocrine Society’s meeting, investigating the effect of liraglutide 3 mg in adults...
New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation
23 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation...
Sanofi reports positive Phase 3 results for Toujeo®
19 June 2014 | By Sanofi
Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...
Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration
19 June 2014 | By Pfizer
Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets...
Janssen announces License Agreement with Vertex to develop novel treatment for influenza A
19 June 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc. announced that it has entered into an exclusive license agreement with Vertex Pharmaceuticals...
Brintellix® demonstrated a statistically significantly superior improvement compared to escitalopram in improving sexual functioning in well treated patients suffering from depression and experiencing treatment-emergent sexual dysfunction
19 June 2014 | By H. Lundbeck A/S
Lundbeck will present results about sexual functioning from a head-to-head study of Brintellix® (vortioxetine) vs. escitalopram in patients with well treated Major Depressive Disorder...
Teva reaches settlements in NUVIGIL® patent case
18 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that it has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to U.S. Patent 7,132,570 for Teva’s wakefulness product, NUVIGIL® (armodafinil) tablet...
Novartis emphasizes new focused portfolio at its first Meet Novartis Management investor day
18 June 2014 | By Novartis
For its first "Meet Novartis Management" investor day, Novartis gathered more than 20 of its top executives, drawn from the leadership of Pharmaceuticals...
Bristol-Myers Squibb announces dividend
18 June 2014 | By Bristol-Myers Squibb
The Board of Directors of Bristol-Myers Squibb Company declared a quarterly dividend of thirty-six cents per share on the $.10 par value Common Stock of the corporation...
GEA’s Pharmaceutical GMP Spray Drying facility receives approval for use in the production of human medicinal products for commercial use
17 June 2014 | By GEA Group
GEA Process Engineering’s Pharmaceutical GMP Spray Drying facility in Copenhagen, Denmark has been granted authorization by the Danish Health and Medicines Authority for spray drying of human medicinal products for commercial use...
Tecan offers Dual Z arm for Cavro® Omni Robot
17 June 2014 | By kdm communications
Tecan has introduced a Dual Z arm for the popular Cavro® Omni Robot...
Novartis submits application to the FDA for meningitis B vaccine candidate Bexsero® to help protect US adolescents and young adults
17 June 2014 | By Novartis
Novartis announced the submission of a Biologic License Application to the US Food and Drug Administration for marketing approval for the use of Bexsero® (Multicomponent Meningococcal Group B Vaccine...
Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials
17 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin...
